QT Imaging
Builds FDA-cleared breast acoustic CT scanning and viewing software.
Something off on this page? Send us feedback.
Profile
Develops and commercializes the Breast Acoustic CT Scanner and QTviewer imaging software. The business operates as one reportable segment and also pursues scanner distribution and QTI Cloud SaaS subscriptions.
Develops and commercializes the Breast Acoustic CT Scanner, an FDA-cleared transmission-and-reflection ultrasonic 3D breast-imaging system. QTviewer provides viewing and analysis of the scanner's co-registered volumetric datasets and is designed for DICOM and PACS workflows.
The business has one operating and reportable segment centered on this scanner platform, and its product path remains concentrated rather than portfolio-driven. Commercialization depends on scanner distribution and, where applicable, QTI Cloud SaaS subscriptions; a Saudi agreement covers both. FDA clearance and a Category III CPT code scheduled to take effect in 2027 shape the product's route to use and reimbursement.
Company facts
Key statistics
Year to date −48.8% · Average volume (30d) 40.2K
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 12, 2026Q2 FY26 | −$0.22 | −$0.75 | −240.9% | $7.6M | $7.4M | −2.2% | −5.32% |
| May 13, 2026Q1 FY26 | −$0.14 | −$0.25 | −85.2% | $6.4M | $6.5M | +1.3% | +6.17% |
| Feb 18, 2026Q4 FY25 | −$0.12 | −$0.10 | +13.0% | $7.8M | $8.3M | +6.8% | +5.45% |
| Nov 11, 2025Q3 FY25 | −$0.03 | −$0.28 | −833.3% | $5.4M | $4.2M | −21.7% | −1.44% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $2.8M | $3.7M | $4.2M | $8.3M | $8.3M | $7.4M | |
| Gross profit | $1.8M | $1.8M | $1.8M | $3.1M | $3.1M | $3.1M | |
| Operating income | −$1.0M | −$1.0M | −$1.7M | −$700.2K | −$700.0K | −$1.9M | |
| Net income | −$11.1M | −$4.0M | −$4.6M | −$1.4M | −$1.4M | −$11.1M | |
| Diluted EPS | −$0.40 | −$0.14 | −$0.47 | −$0.10 | −$0.10 | −$0.75 | |
| Gross margin | 64.8% | 49.9% | 43.0% | 38.0% | 38.0% | 41.2% | |
| Operating margin | -37.2% | -28.5% | -39.4% | -8.5% | -8.5% | -25.1% |
Fiscal years (4-quarter sums)FY22 $0 · FY23 $0 · FY24 $4.9M · FY25 $18.9M
Revenue by product · Q1 FY26
Revenue by geography · Q1 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $11.0M · Total debt $4.3M · Total assets $30.6M · Shareholders' equity $2.2M
Dividends
No dividends on record.
Ownership
Shares outstanding 13.77M · Float 7.65M · 55.6% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| John C. Jr Klock · director, 10 percent owner: | 2.88M | 20.95% | Form 4 | Mar 24, 2026 |
| Emil D. Kakkis and Jenny Soriano | 1.40M | 5.10% | 13G | Mar 26, 2025 |
| Lynrock Lake LP | 1.15M | 8.39% | 13F | May 15, 2026 |
| Alyeska Investment Group, L.P. | 702.8K | 5.10% | 13F | May 15, 2026 |
| James S. Greene · director | 631.6K | 4.59% | Form 4 | Mar 24, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
View detailsPeers
- GE HealthCare
Automated 3D breast-ultrasound platform for dense-tissue screening
- Philips (ADR)
Diagnostic-imaging supplier with ultrasound, MRI, and breast-care workflows
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| QT Imaging | $3.09 | +1.48% | $42.5M | — | — | 1.5 | +103.2% |
| GE HealthCare | $71.73 | −0.01% | $32.40B | 20.8 | 13.8 | 1.6 | +5.8% |
| Philips (ADR) | $26.72 | +0.06% | $26.12B | 19.9 | 13.7 | 1.3 | −2.9% |
| Median | 20.3 | 13.7 | 1.4 | +1.4% |